Vanguard Capital Management
RNTX

Vanguard Capital Management’s Rein Therapeutics RNTX Stock Holding History

Vanguard Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Buy
3,377,910
+2,379,389
+238% +$2.88M ﹤0.01% 3235
2026
Q1 		$1.3M Buy
+998,521
New +$1.24M ﹤0.01% 3492

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management's RNTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Rein Therapeutics (RNTX) stake by 238% in Q2 2026, buying an estimated $2.88M and bringing the position to 3,377,910 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3235.

Vanguard Capital Management first reported a position in RNTX in Q1 2026 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Vanguard Capital Management held 3,377,910 shares of Rein Therapeutics worth $3.51M as of Q2 2026.
  • Vanguard Capital Management bought 2,379,389 Rein Therapeutics shares in Q2 2026, an estimated $2.88M.
  • Rein Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3235 holding.
  • Vanguard Capital Management first reported a position in Rein Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.